

FORM 7

MONTHLY PROGRESS REPORT

For May 2020

Name of Listed Issuer: Liberty Health Sciences Inc. (the "Issuer" or "Company").

Trading Symbol: LHS

Number of Outstanding Listed Securities: 346,090,635 common shares

Date: June 5, 2020

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

In March 2020, the World Health Organization categorized coronavirus disease 2019 ("COVID-19") as a pandemic. This has resulted in significant economic uncertainty and consequently, it is difficult to reliably measure the potential impact of this uncertainty on our future financial results.

2. Provide a general overview and discussion of the activities of management.

In Florida, in addition to initiating production expansion activities at its Liberty 360° Innovation Campus in Gainesville, management continues to seek and open potential dispensary sites.

3. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None to report in the month of May.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None to report in the month of May.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None to report in the month of May.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None to report in the month of May.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None to report in the month of May.

8. Describe the acquisition of new customers or loss of customers.

The Company continues to grow its number of patients as the overall Florida market increases in terms of registered patients and as the Company expands its footprint in the state. The Florida market has also reacted positively to Liberty's whole flower products and continues to assist to expand Liberty's customer base.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

None to report in the month of May.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

The Company continues to add personnel in the areas of patient care and processing in the Florida operations and dispensaries with the expected opening of additional dispensaries over the next 30-60 days.

There were no significant terminations or lay-offs in the month of May.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None to report in the month of May.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None to report in the month of May.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.
No new debt to report for the month of *May*.

14. Provide details of any securities issued and options or warrants granted.
None to report in the month May.

15. Provide details of any loans to or by Related Persons.
None to report in the month of May.

16. Provide details of any changes in directors, officers or committee members.
None to report in the month May.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.
None to report in the month May.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. To the best of the undersigned's knowledge and belief, as of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that, to the best of the undersigned's knowledge and belief, the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. To the best of the undersigned's knowledge and belief, all of the information in this Form 7 Monthly Progress Report is true.

Dated June 5, 2020.

Sheri Cholodofsky
Name of Director or Senior Officer

"Sheri Cholodofsky"
Signature

CFO
Official Capacity

<i>Issuer Details</i> Name of Issuer Liberty Health Sciences Inc.	For Month End May 31, 2020	Date of Report YY/MM/DD 20/06/05
Issuer Address 78 Gwendolen Crescent		
City/Province/Postal Code Toronto, ON, Canada M2N 2L7	Issuer Fax No.	Issuer Telephone No.
Contact Name Sheri Cholodofsky	Contact Position CFO	Contact Telephone 833 254 4877
Contact Email Address ir@libertyhealthsciences.com	Web Site Address https://libertyhealthsciences.com/	